文献速递甲状腺与颈部外科

Bethesda III、IV、V类甲状腺结节:结节大小能否预测恶性?

Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
PubMed 文献 · J Am Coll Surg · 2017-02-20

该回顾性研究纳入1104例接受甲状腺细针穿刺及后续甲状腺切除术的患者,其中461例(42%)细胞学结果不确定。分析发现,结节大小在所有不确定细胞学病变中与恶性风险无显著关联(OR 0.83;95%CI 0.76-1.00;p=0.051)。仅在Hürthle细胞肿瘤中,结节增大与恶性风险增加相关(OR 2.17;95%CI 1.16-4.04;p=0.01)。

要点

  • 在AUS/FLUS、SFN和SM类结节中,结节大小不能预测恶性。
  • Hürthle细胞肿瘤结节越大,恶性风险越高(OR 2.17)。
  • 临床决策仍需结合临床情况、机构恶性率和分子检测。

核心结论

  • 较大的Hürthle细胞肿瘤结节更可能为恶性,但结节大小在AUS/FLUS、SFN或SM患者中不能单独预测恶性。

研究设计与样本

  • 回顾性研究,纳入1104例接受甲状腺细针穿刺及后续甲状腺切除术的患者,其中461例(42%)细胞学结果不确定。

主要发现

  • 最终组织学显示121例(28%)索引病变为恶性(AUS 23%;FLUS 14%;SFN 22%;HCN 25%;SM 69%)。
  • 在所有不确定细胞学病变中,结节大小与恶性风险无显著关联(OR 0.83;95%CI 0.76-1.00;p=0.051)。
  • 在Hürthle细胞肿瘤中,结节增大与恶性风险增加相关(OR 2.17;95%CI 1.16-4.04;p=0.01)。

临床怎么用

  • 对于AUS/FLUS、SFN或SM结节,不应仅依据大小判断恶性风险。
  • 对于Hürthle细胞肿瘤,结节较大时需更警惕恶性可能。
  • 治疗决策应结合临床情况、机构特异性恶性率和分子检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association of tumor size with malignancy in thyroid nodules with indeterminate cytology (atypia of undetermined significance [AUS]/follicular lesion of undetermined significance [FLUS], suspicious for follicular neoplasm [SFN]/Hürthle cell neoplasm [HCN], and suspicious for malignancy [SM]) has not been clearly studied. STUDY DESIGN: We retrospectively identified 1,104, patients who underwent thyroid FNA and subsequent thyroidectomy. Patients with indeterminate cytology were reviewed. The size of the nodule was determined by ultrasound. Malignancy was confirmed by final histology. Logistic regression modeling was performed to determine if nodule size was associated with malignancy. RESULTS: There were 461 (42%) patients who had indeterminate cytology by FNA. The median nodule size of all indeterminate lesions was 2.1 cm (range 0.5 to 10 cm). The median nodule size for AUS/FLUS was 2.1 cm (range 0.7 to 8 cm), for SFN was 2.4 cm (range 0.5 to 10 cm), for HCN was 2.2 cm (range 0.5 to 9.3 cm), and for SM was 1.6 cm (range 0.5 to 6 cm). On final histology, 121 (28%) index lesions were malignant (AUS 23%; FLUS 14%; SFN 22%; HCN 25%; SM 69%). On logistic regression, nodule size was not associated with increased odds of malignancy in all lesions with indeterminate cytology (odds ratio [OR] 0.83; 95% CI 0.76 to 1.00; p = 0.051). Nodule size was not associated with malignancy in the index nodule of AUS/FLUS, SFN, or SM lesions. Increased nodule size was associated with malignancy in HCN lesions (OR 2.17; 95% CI 1.16 to 4.04; p = 0.01). CONCLUSIONS: The findings of this study suggest that larger HCN nodules are more likely to be malignant. Nodule size alone was not predictive of malignancy in patients with AUS/FLUS, SFN, or SM. Clinical picture, institution-specific malignancy rates, and molecular testing continue to be important factors guiding treatment.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Kiernan CM, Solórzano CC. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy? J Am Coll Surg. 2017. PMID: 28223197. doi:10.1016/j.jamcollsurg.2017.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。